Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2022; 76(3): 268–271.

Subcutaneous Infliximab – the beginning of the era of bio­betters in the treatment of immune-mediated inflammatory diseases

Kateřina Michnová1

+ Affiliation


Print pdf

Credited self-teaching test

Start test

Most Read (last 6 month)

  1. Colorectal cancer screening in the Czech Republic
  2. Pancreatic cancer surveillance in high-risk individuals Position statement of professional societies
  3. Trends in premature mortality from digestive system cancers in Slovakia in the years 2011–2020: 8 diagnoses over 10 years
  4. Results from the evaluation of colorectal cancer screening in the Czech Republic
  5. Mixed adenoneuroendocrine carcinoma of the stomach – a case report
  6. Subcutaneous infliximab in the treatment of refractory Crohn‘s disease patients – a pilot study of drug immunogenicity
  7. Urolithiasis in patients with inflammatory bowel disease – possibilities of prevention and metabolic influence
  8. Subcutaneous infliximab – treatments and new possibilities after clinical practice